Accuracy of rapid blood coagulation testing device FibCare® in a tertiary emergency department

Abstract Aim FibCare® is a novel point‐of‐care testing device enabling prompt evaluation of fibrinogen levels. This study aimed to investigate the accuracy of FibCare® at a tertiary emergency department. Methods Blood specimens obtained at a tertiary emergency medical center between October 1, 2021,...

Full description

Saved in:
Bibliographic Details
Main Authors: Yutaka Mihara, Kenta Komoriya, Kei Hagiwara, Yasuhito Hatanaka, Keita Shibahashi, Mayu Hikone, Kazuhiro Sugiyama
Format: Article
Language:English
Published: Wiley 2024-01-01
Series:Acute Medicine & Surgery
Subjects:
Online Access:https://doi.org/10.1002/ams2.934
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Aim FibCare® is a novel point‐of‐care testing device enabling prompt evaluation of fibrinogen levels. This study aimed to investigate the accuracy of FibCare® at a tertiary emergency department. Methods Blood specimens obtained at a tertiary emergency medical center between October 1, 2021, and April 30, 2023, were evaluated. The correlation between the fibrinogen levels assessed via FibCare® and those via the Clauss method was evaluated using the Spearman's test. The discrepancy between the two measurement methods was assessed according to fibrinogen level and diagnosis. Results A total of 177 specimens from 147 patients were eligible for the analysis. The median age of the patients was 49 years, and 109 (61.6%) were men. The two measurements had statistically significant but moderate correlation (p < 0.001, ρ = 0.76). FibCare® missed 14 out of 35 cases from patients with hypofibrinogenemia (fibrinogen ≤150 mg/dL assessed by the Clauss method). The discrepancy between the two measurements was significantly greater in specimens with lower fibrinogen levels and those obtained from patients following trauma. Conclusions FibCare®, a novel point‐of‐care testing device, can be compatible with the Clauss method. However, clinicians should be aware of the risk that FibCare® may underestimate fibrinogen reduction, especially in severe cases and trauma cases.
ISSN:2052-8817